)
Visual
test
FluoGuide
FluoGuide (FLOU) investor relations material
FluoGuide SEB Nordic Seminar presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.SEB Nordic Seminar presentation summary7 Jan, 2026
Vision and market need
Aims to enhance surgical precision and efficiency through fluorescence-guided surgery, collaborating with MedTech companies and surgeons to improve cancer patient outcomes.
Cancer surgery demand is rising, with 20 million new cancer diagnoses and 12 million surgeries annually; 50% of patients experience local recurrence.
By 2030, 45 million surgical procedures are projected annually worldwide.
Technology and clinical progress
FG001 is a uPAR-targeted imaging agent, injected before surgery to guide tumor removal, with strong clinical data in multiple cancer types.
uPAR is highly expressed in solid tumors and minimally in normal tissue, supporting broad applicability.
Positive phase II clinical data in brain, head and neck, and lung cancers; over 100 patients treated with good tolerability.
Orphan Drug Designation granted for high-grade glioma in the US, with positive FDA feedback and IND submission planned for January 2026.
Partnerships, business model, and financials
Strategic, non-exclusive partnerships with leading MedTech firms (Zeiss, Olympus, SurgVision, Intuitive Surgical) to expand reach and adoption.
FG001 is compatible with all major surgical equipment, reducing barriers to adoption.
Business model includes recurring revenue from FG001 sales and synergies with surgical systems; pricing set at $4,000–5,000 per dose.
Successful capital raise of SEK 104 million and extended credit facility secure funding into 2027.
HGG regulatory path: implications for other indications?
Elaborate on 2026 partnership strategy and goals
Photosensitizer therapy: commercialization timeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 5 FebGEVO
Scaling low-carbon fuel production and software, targeting major growth and plant expansion. - 5 FebTPG
AUM reached $303B (+23% YoY) in 2025, with record fundraising and strong 2026 outlook. - 5 FebMAA
2026 guidance projects modest growth as fundamentals recover and supply pressures ease. - 5 FebXFAB
2025 revenue up 7% to $873M; Q4 EBITDA hit by SiC one-off, 2026 outlook cautious. - 5 FebSPB
Net sales fell 3.3% but net income rose 19.5%; 2026 guidance reiterated. - 5 FebESS
Core FFO and same-property growth exceeded guidance, with strong liquidity and outlook. - 5 FebCOP
Earnings fell on lower prices, but production grew and $9B was returned to shareholders. - 5 FebHP
EBITDA beat, $1B+ revenue, net loss from impairment, and accelerated debt repayment. - 5 FebGBT
2025 revenue fell 3.5% at CER, but EBITDA margin and cash flow outlooks remain positive. - 5 FebORLY
Record 2025 results, 6% sales and 10% EPS growth, with strong 2026 outlook.
Next FluoGuide earnings date
Q4 202525 Feb, 2026
FluoGuide
Next FluoGuide earnings date
Q4 202525 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
FluoGuide is a Danish clinical-stage biotech company specializing in the development of products used to improve cancer surgery. FluoGuide's main product, FG001, is designed to illuminate brain cancer cells during surgery, enabling surgeons to distinguish them more easily from healthy tissue. FG001 is designed to bind specifically to cancer cells, making them visible under a special light during surgery. This aims to reduce the risk of leaving cancerous tissue behind, potentially increasing the success rate of surgeries. The company is also actively researching whether its fluorescent technology can be employed to potentially improve surgery outcomes for a variety of different cancers. FluoGuide is headquartered in Copenhagen, and its shares are listed on Nasdaq Stockholm.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage